Showing 2941-2950 of 5771 results for "".
- Alcon Unveils PRECISION7 1-Week Contact Lens with ACTIV-FLO Technologyhttps://modernod.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/Alcon announced the US launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO system, these lenses are designed to deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. [1]
- Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2https://modernod.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2/2482531/Neurotech Pharmaceuticals announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17
- Harrow Partners with Asembia to Create Digital Services and Hub Support for Harrow’s Branded Eye Care Productshttps://modernod.com/news/harrow-partners-with-asembia-to-enhance-provider-and-patient-experience-through-nationwide-digital-services-and-hub-support-for-harrows-branded-eye-care-products/2482530/Harrow announced the nationwide launch of a new digital patient access solution in collaboration with Asembia. This multi-year partnership is designed to expand access to Harrow’s ophthalmic branded products, including Flarex, Ilevro, Maxidex, Maxitrol, Natacyn, Nevanac, Tobradex ST, Verkaz
- Arctic Vision Executes Collaboration Agreement with Santen for ARVN001 for the Treatment of Uveitic Macular Edemahttps://modernod.com/news/clearside-biomedical-partner-arctic-vision-executes-commercial-collaboration-agreement-with-santen-pharmaceutical-co-for-arvn001-suprachoroidal-space-injection-therapy-for-the-treatment-of-uveitic-macular-edema/2482529/Clearside Biomedical announced that its Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical for ARVN001, branded in the United States as Xipere, for the treatment of uveitic macular edema
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- FELIQS Receives FDA Fast Track Designation for FLQ-101, a First-in-Class Small Molecule to Prevent Retinopathy of Prematurityhttps://modernod.com/news/feliqs-receives-fda-fast-track-designation-for-flq-101-a-first-in-class-small-molecule-to-prevent-retinopathy-of-prematurity/2482526/FELIQS announced that the US Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the United States and Ja
- GenSight Biologics Publishes Meta-Analysis on Efficacy of Treatments for Leber Hereditary Optic Neuropathyhttps://modernod.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/GenSight Biologics announced the publication of a meta-analysis evaluating visual outcomes in patients with Leber Hereditary Optic Neuropathy (LHON) due to the MT-ND4 mitochondrial gene mutation. This mutation, known as ND4-LHON, is the most common cause of the disease and is associated with the
- Astellas Withdraws European Application for Avacincaptad Pegol for GAhttps://modernod.com/news/astellas-withdraws-european-application-for-investigational-geographic-atrophy-treatment/2482517/Astellas Pharma announced it is withdrawing its marketing authorization application for avacincaptad pegol (ACP) from the European Medicines Agency (EMA). ACP, an investigational intravitreal treatment designed to inhibit the complement C5 protein, was developed for geographic atrophy (
- EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyuhttps://modernod.com/news/eyepoint-pharmaceuticals-doses-first-patient-in-phase-3-lugano-trial-for-wet-amd-therapy-duravyu/2482512/EyePoint Pharmaceuticals announced dosing of the first patient in its phase 3 LUGANO clinical trial of Duravyu. This investigational sustained delivery therapy, formerly known as EYP-1901, aims to treat wet age-related macular degeneration (AMD) using a patent-protected formulation of vorolanib,
- Study of Alkeus' Oral Gildeuretinol Demonstrate Trend in Slowing GA Progression and Visual Function Improvementhttps://modernod.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/Alkeus Pharmaceuticals announced findings from its SAGA study, which evaluated the investigational oral therapy gildeuretinol (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study showed a statistically significant reduction in GA l